Centre National De La Recherche Scientifique

Institut Curie

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Université Pierre Et Marie Curie (paris Vi)

Other

Sylvie Robine

Daniel Louvard

David Grierson

Ludger Johannes

Jean-Claude Florent

Jacky Roger

Philipe Maillard

Andre Choulika

Alphonse Garcia

Monique Arpin

Eric Pringault

Charles Babinet

Brigitte Dudouet

Frederic Jaisser

Michel Cohen-Tannoudji

Manuel Buchwald

Xavier Sastre-Garau

François Amblard

Alexandre Edelman

Marie-Alyette Costa De Beauregard

Dominique Chesnoy-Marchais

Ming Chen

Frédéric Jaisser

Daniel Pinto

The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gbreceptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein

[object Object]

Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors

The invention relates to new compounds for cancer therapy or diagnosis and to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein-STxB is the Shiga Toxin B subunit or a functional equivalent thereof, -Z(n) wherein n is 0 or 1, Z is an amino-acid residue devoid of sulfydryl groups, or is a polypeptide, -T is a molecule linked by a covalent bound to the S part of Cys, selected from: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, - Y(m) wherein m is 0 or 1, Y is a linker between T and Cys, which is either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into cells.

The invention relates to regulatory sequences of the mouse villin gene that efficiently drive transgenic expression in immature and differentiated epithelial cells of the intestine and uro-genital tracts. The invention also relates to recombinant constructs comprising said regulatory sequences, for the control of the targeted expression of determined nucleic acid sequences so-called (heterologous sequences or also transgenes), in cells or tissues originating from the intestinal mucosa. A further object of the invention is to provide cells, tissues or organisms including animals, expressing said determined nucleic acid sequences in a targeted manner.

Regulatory sequences of the mouse villin gene&#x2014;use in transgenesis

An installation is provided for multi-dimensional non-linear imaging of a material comprising intrinsic chromophores, using laser scanning. This installation comprises i) at least one source () of time stamp pulses of synchronized photons, ii) means () for locally focusing the pulses on a material to cause its intrinsic chromophores to absorb groups of at least two synchronized photons to produce response photons, iii) means () for directing the response photons to at leat one collecting zone, iv) means () for collecting the response photons in the collecting zone(s) whatever their energy, v) processing means for converting the collected photons into data at least representative of their number and storing them in correspondence with at least the time stamp pulses that cause the material to produce the response photons, vi) means for scanning () the pulses through a chosen area of the material, and vii) means for delivering from said data stored an image representative of said material chosen area, with a sub-millimeter resolution, and in function of the respective time stamp pulses of data.

Multi-photon imaging installation

The invention relates to methods of introducing a heterologous DNA sequence into a mouse embryonic stem cell wherein the DNA sequence is inserted by homologous recombination into a villin gene/I-SceI hybrid by creating a double strand break with I-SceI meganuclease. Subsequently, the mouse embryonic stem cells can be used to generate a transgenic mouse comprising the heterologous DNA sequence. Additionally, the methods can be used for gene replacement in ovo where a mouse oocyte containing a villin gene/I-SceI hybrid within its genome exists or is first generated. More generally, the methods can be used for the targeted insertion of a heterologous DNA sequence into any cell containing a villin gene/I-SceI hybrid sequence within its genome.

I-Sce I induced gene replacement and gene conversion in embryonic stem cells

The invention relates to a recombinant nucleic acid, characterized in that it comprises:

Stable cell lines expressing the CFTR protein or a mutant of this

This invention relates to a method of constructing a villin gene hybrid by inserting an I-Sce I restriction site next to or within a gene or cDNA encoding a villin protein. The insertion site of the I-Sce I restriction site is chosen as to provide a first downstream part and a second upstream part from the site, containing at least twelve nucleotides of the gene or cDNA encoding the villin protein. Furthermore, the insertion of the restriction permits a high frequency of homologous recombination events. The villin gene hybrid may be used to transfect eukaryotic cells, and particularly, embryonic stem cells.

I Sce I-induced gene replacement and gene conversion in embryonic stem

Antibodies, both polyclonal and monoclonal, recognize and bind human villin. Hybridomas, producing monoclonal antibodies which bind human villin, are also provided.

Antibodies which recognize and bind human villin

In vitro diagnosis of malignant cells originating in the digestive tract by placing a biological specimen in contact with a reagent recognizing the gene coding for human villin.

Agents for the in vitro diagnosis of malignant cells originating in the

Growing community of inventors

Vanves, France

Sylvie Robine